-
NEJM: Enmeluamine used to treat desomnivoic prostate cancer
Time of Update: 2020-06-05
Preliminary test results showed that for patients with non-metastatic, de-resistant prostate cancer treated with androgen deprivation, enmelulamine significantly improved the non-metastatic surviva
-
New drug for multiple myeloma! Sanofi CD38 antibody Sarclisa approved by the European Union, sword refers to Johnson and Johnson's annual sale of $3 billion heavy drug Darzalex
Time of Update: 2020-06-05
04 June 2020 / Biovalley BIOON / -- Sanofi recently announced that the European Commission (EC) has approved the CD38 target antibody drug Sarclisa (isatuximab), combined with Pomadomide and Dexa
-
Blood: DNA methylation spectrum identifies two giant globulinemia (WM) subtypes
Time of Update: 2020-06-05
Epigenetic changes in B-cell differentiation have produced DNA methylation characteristics specific to the B-cell subgroup, including memory B cells (MBCs) and plasma cells (PCs) Waldenstrom Megagl
-
How to treat drug-resistant rare gynecological cancers? Immunotherapy Avelumab shows off
Time of Update: 2020-06-05
Pregnancy Nourishing Cell Tumor (GTT) is a very rare gynaecological cancer that occurs during or after pregnancy GTT is caused by abnormal growth of the endometrial during conception Avelumab is a
-
ASCO Frontiers . . . A summary of major breakthroughs in CAR-T therapy for relapse/incurable lymphoma
Time of Update: 2020-06-05
ASCO Frontiers Car-T therapy for recurrent/incurable lymphoma major breakthrough summary embedded antigen receptor T-cell therapy (chimeric antigen receptor T-celltherapy, CAR-T) as the more ef
-
ASCO 2020: HR-HER2-Advanced Breast Cancer Endolastal Metastay Treatment Options?
Time of Update: 2020-06-05
Primary drug resistance, visceral metastasis are the factors of poor prognosis of HR-HER2-advanced breast cancer, and are also difficult to overcome in individual endocrine therapy Previous studies
-
Blood: IKAROS and CK2 regulate high-risk B-ALL BCL-XL expression and chemotherapy sensitivity
Time of Update: 2020-06-05
High-risk B-cell acute lymphoblastic leukemia (B-ALL) is an invasive disease characterized by chemotherapy resistance A common feature of high-risk B-ALL is the loss of function of the tumor suppre
-
NEW DISCOVERY: ANTIMALARIAL DRUG PHENYLALCOHOL IS EXPECTED TO TREAT BRAIN TUMORS
Time of Update: 2020-06-05
Introduction: polymorphic glioblastoma is a type of glioma (GBM) and one of the most malignant brain tumors Glioma is the most common malignant tumor in the skull, accounting for 40 to 50 percent
-
Roche's Tecentriq/Avastin combination gets U.S. approval - the first immunotherapy for cancer that cannot be removed or metastatic
Time of Update: 2020-06-05
U.S regulators have approved a combination of Roche's PD-L1 monosero-tecentriq (atezolizumab) and anti-angiotherite-based monoserotrophilia monovastin (bevacionzumab) to treat unable to remove or m
-
Liver Int: Gallstones Increase The Risk of Liver and Pancreatic Cancer! Kailua research nearly 80,000 people
Time of Update: 2020-06-05
Gallstones are common, and a recent study of nearly 80,000 people showed that gallstones increase the risk of gastrointestinal cancer studies showed that screening detected gallstones increased th
-
NEJM: Oral Relugolix For Advanced Prostate Cancer
Time of Update: 2020-06-05
The oxyperolin injection is the standard drug for prostate cancer, and researchers recently examined the efficacy of the oral gonadotropin-releasing hormone antagonist Relugolix patients with ad
-
Recurrence of treatment or breakthrough for kidney cell carcinoma: FDA approves Tivozanib's NDA
Time of Update: 2020-06-05
Pharmaceutical company AVEO announced today that the U.S FDA has approved Tivozanib's new drug application (NDA) for the treatment of recurrent refractory renal cell carcinoma (RCC), the company's
-
ASCO 2020 Regret! Early local therapy failed to improve the overall survival rate of women with primary stage IV breast cancer
Time of Update: 2020-06-05
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) has been successfully concluded, and this academic feast has won the attention of oncologists around the world The most-w
-
Comparison of three-way effect stoic sedation for surgical removal of olphinmenacoma
Time of Update: 2020-06-03
Ref: Liu JK, et al. Neurosurg Focus 2018 Apr;44 (4): E8 doi: 10.3171/2018.1.FOCUS17722.: olfactory groove meningiomas, OGMs) originated from the olfactory grouse, sieve and forehead sieves at the
-
CPC width does not affect the efficacy of endoscopic EEA excision to remove cranial pharynx tumor
Time of Update: 2020-06-03
Ref: Omay SB, et al. J Neurosurg 2018 Sep;129 (3):642-647 doi: 10.3171/2017.6.JNS163188 Epub 2017 Nov 24 cranial pharynx tumor originated in the pituitary handle, and the lesions of adult patients
-
Nature: Clinical study of glioma diagnosis through cerebrospinal biopsy
Time of Update: 2020-06-03
Alexandra M Miller of memorial Sloan Kettering Cancer Center in the United States believes ctDNA sequencing in cerebrospinal fluid (CSF) may provide another way to detect tumor genotypes The researche
-
Experimental Study of EGFR Inhibitor Controlling PDX Model GBM
Time of Update: 2020-06-03
Erlotinib concentration determination of subcutaneous or intracranial PDX model GBM GBM was carried out using matrix-assisted laser desorscent ionizing/ionizing mass spectrometry (MALDI MSI) and liqui
-
Risk stratification and treatment of non-WNT/non-SHH myelin tumor
Time of Update: 2020-06-03
Ref: Goschzik T, et al Lancet Oncol 2018 Dec;19 (12):1602-1616 doi: 10.1016/S1470-2045 (18) 30532-1 Epub 2018 Nov 1 50%-60% myelin tumors are standard risk-class tumors, i.e non-high-risk diseases,
-
Preoperative embolism for the evaluation of cranial meningioma
Time of Update: 2020-06-03
Ref: Ilyas A, et al . J Clin Neurosci. 2019 Jan;59:259-264 doi: 10.1016/j.jocn.2018.06.022 Epub 2018 Sep 29 : The use of microsurgery to remove a cranial subcranial meningioma is challenging to rem
-
Monitoring and treatment recommendations for adult survivors of childhood brain tumours
Time of Update: 2020-06-03
After treatment with chemical medicine, memory and behavior must be checked regularly and, if necessary, with the intervention of neurology, psychology and rehabilitation specialists to improve the qu